In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Frontiers in Cancer Immunotherapy 2020

Frontiers in Cancer Immunotherapy 2020

Monday, May 11 - Tuesday, May 12, 2020

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Cancer Discussion Group

The New York Academy of Sciences

 

Groundbreaking advances in cancer immunotherapy have dramatically changed the landscape of patient care. Great clinical successes have been achieved in several cancers, but others, including many solid tumors, remain refractory to current treatments. While the immune characteristics of the tumor microenvironment are correlated with therapeutic response, methods to use this information to predict patient outcome are lacking.

This two-day meeting will convene experts in tumor immunology, cancer genetics and computational biology to discuss innovative methods to analyze both the tumor and the host immune system and highlight the links between tumor genotype, immune phenotype and patient response. Key themes under discussion will include tumor evolution, neoantigens, novel therapeutic targets, and mechanisms driving the emergence of resistance to current therapy.

Registration

Member
By 03/30/2020
$250
After 03/30/2020
$340
Nonmember Academia, Faculty, etc.
By 03/30/2020
$400
After 03/30/2020
$540
Nonmember Corporate, Other
By 03/30/2020
$475
After 03/30/2020
$640
Nonmember Not for Profit
By 03/30/2020
$400
After 03/30/2020
$540
Nonmember Student, Undergrad, Grad, Fellow
By 03/30/2020
$270
After 03/30/2020
$365
Member Student, Post-Doc, Fellow
By 03/30/2020
$220
After 03/30/2020
$300
Earlybird Registration:
2
days
left
Deadline:
0
days
left

Scientific Organizing Committee

Chris Boshoff, MD, PhD
Chris Boshoff, MD, PhD

Pfizer

Renier Brentjens, MD, PhD
Renier Brentjens, MD, PhD

Memorial Sloan Kettering Cancer Center

Padmanee Sharma, MD, PhD
Padmanee Sharma, MD, PhD

MD Anderson Cancer Center

George Zavoico, PhD
George Zavoico, PhD

B. Riley FBR

Sara Donnelly, PhD
Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal, PhD
Sonya Dougal, PhD

The New York Academy of Sciences

Speakers

Elizabeth Jaffee, MD
Elizabeth Jaffee, MD

Johns Hopkins University School of Medicine

Catherine Wu
Catherine Wu, MD

Dana-Farber Cancer Institute, Harvard Medical School

Charles Swanton, FRCP, PhD, FRS
Charles Swanton, FRCP, PhD, FRS

The Francis Crick Institute

Elaine Mardis
Elaine Mardis, PhD

The Ohio State University

Crystal Mackall
Crystal Mackall, MD

Stanford University

Sumit Subudhi, MD, PhD
Sumit Subudhi, MD, PhD

MD Anderson Cancer Center

Robert Schreiber
Robert Schreiber, PhD

Washington University School of Medicine in St. Louis

Stefani Spranger, PhD
Stefani Spranger, PhD

Massachusetts Institute of Technology

David Chang, MD, PhD
David Chang, MD, PhD

Allogene

Jeffrey Sosman
Jeffrey Sosman, MD

Feinberg School of Medicine, Northwestern University

Sangeeta Goswami, MD, PhD
Sangeeta Goswami, MD, PhD

MD Anderson Cancer Center

Max Topp, MD
Max Topp, MD

University of Würzburg

Catherine Bollard
Catherine Bollard, MD, MB, ChB

Children's National Hospital

Mikala Egeblad, PhD
Mikala Egeblad, PhD

Cold Spring Harbor Laboratory

Benjamin Greenbaum, PhD
Benjamin Greenbaum, PhD

Icahn School of Medicine at Mount Sinai

James Allison, PhD
James Allison, PhD

MD Anderson Cancer Center

Andrew Sewell, PhD
Andrew Sewell, PhD

Cardiff University


Monday

May 11, 2020

8:00 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks

Session 1

9:15 AM

Immunotherapies for Solid Tumors

Speaker

Elizabeth Jaffee, MD
Johns Hopkins School of Medicine
10:00 AM

Immune Checkpoint Blockade in Cancer Therapy: Historical Perspective, New Opportunities

Speaker

James Allison, PhD
MD Anderson Cancer Center
10:30 AM

Networking Coffee Break

11:00 AM

Allogeneic CAR T Cell Therapies for Cancer

Speaker

David Chang, MD, PhD
Allogene
11:30 AM

T cell Therapies for Cancer: Overcoming Tumor Immune Evasion

Speaker

Catherine Bollard, MD, MB, BCh
Children's National Hospital and The George Washington University
12:00 PM

Networking Lunch and Poster Session

Speakers

Even numbered Posters: 12:30 PM - 1:00 PM
Odd numbered Posters: 1:00 PM - 1:30 PM

Session 2

1:30 PM

Panel Discussion: Allogeneic vs. Autologous Cellular Therapies

Speakers

Renier Brentjens, MD, PhD (moderator)
Memorial Sloan Kettering Cancer Center
Catherine Bollard, MD, MB, BCh
Children's National Hospital
David Chang, MD, PhD
Allogene

Session 3

2:15 PM

Driving T cells into Tumors: A Role for Personal Cancer Vaccines

Speaker

Catherine Wu, MD
Dana-Farber Cancer Institute and Harvard Medical School
2:45 PM

Modeling Tumor Response to Checkpoint Blockade

Speaker

Benjamin Greenbaum, PhD
Icahn School of Medicine at Mount Sinai
3:15 PM

Ubiquitous T-cell Cancer Targeting via MR1

Speaker

Andrew Sewell, PhD
Cardiff University
3:45 PM

Networking Coffee Break

4:15 PM

Biomarkers and Combination Immunotherapies for Prostate Cancer

Speaker

Sumit Subudhi, MD, PhD
MD Anderson Cancer Center
4:45 PM

Immunogenomics and the TME in Pediatric CNS Cancers

Speaker

Elaine Mardis, PhD
Nationwide Children's Hospital
5:15 PM

Day 1 Closing Remarks

5:20 PM

Networking Reception and Poster Viewing

6:20 PM

Day 1 Adjourns

Tuesday

May 12, 2020

Session 4

9:15 AM

T Cell Based Immunotherapies

Speaker

Crystal Mackall, MD
Stanford University
10:00 AM

Bispecific Antibodies for Cancer Immunotherapy

Speaker

Max Topp, PhD
University of Würzberg
10:30 AM

Networking Coffee Break

11:00 AM

The Mechanistic Basis of Spontaneous and Therapeutically-induced Immune Responses to Cancer

Speaker

Robert Schreiber, PhD
Washington University School of Medicine
11:30 AM

Mechanisms Driving Immunotherapy Toxicity in Cancer Patients

Speaker

Jeffrey A. Sosman, MD
Feinberg School of Medicine, Northwestern University
12:00 PM

Short Talk Selected from Abstracts

12:05 PM

Short Talk Selected from Abstracts

12:10 PM

Short Talk Selected from Abstracts

12:15 PM

Networking Lunch

Session 5

1:30 PM

Panel Discussion: Topic to be Confirmed

Session 6

2:15 PM

Regulation of Cancer Progression by the Tumor Microenvironment

Speaker

Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
2:45 PM

Epigenetic Modulation of T Cells impacts Response to Checkpoint Inhibitors

Speaker

Sangeeta Goswami, MD, PhD
MD Anderson Cancer Center
3:15 PM

Networking Coffee Break

3:45 PM

Impact of Tumor-resident DC on Anti-tumor Immunity

Speaker

Stefani Spranger, PhD
Massachusetts Institute of Technology
4:15 PM

Cancer Evolution and Immune Escape

Speaker

Charles Swanton, FRCP, PhD, FRS
The Francis Crick Institute
5:00 PM

Closing Remarks

5:05 PM

Conference Adjourns